Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01401517 · ClinicalTrials.gov registry record · Phase 2
Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC
A Phase 2 study, sponsored by TheraVasc.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT01401517 is a Phase 2 study that has completed, run by TheraVasc. The registered enrollment target is 55 participants.
The verdict
NCT01401517, a Phase 2 study, has completed, sponsored by TheraVasc.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
Sodium nitrite has been demonstrated to promote new blood vessel growth, speed up wound healing and prevent tissue necrosis in animals. Since patients with PAD experience many of these problems, this study will seek to determine whether this drug, when given orally, could provide the same benefits to patients with PAD.
Interventions
- DRUG sodium nitrite
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01401517
The ClinicalTrials.gov registry entry for NCT01401517 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TheraVasc, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sodium nitrite is the first listed.
NCT01401517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01401517 about?
NCT01401517 is a clinical study titled "Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC". Sodium nitrite has been demonstrated to promote new blood vessel growth, speed up wound healing and prevent tissue necrosis in animals. Since patients with PAD experience many of these problems, this study will seek to determine whether this drug, when given orally, could provide the same benefits t...
What is the current status of trial NCT01401517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2011-07. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01401517?
The interventions under investigation include: sodium nitrite (DRUG).
Who is sponsoring clinical trial NCT01401517?
This trial is sponsored by TheraVasc, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.